| Test Name |
Result |
Flag |
Ref. Range |
Lab |
| FASTING: YES |
|
| VITAMIN B12 |
|
| Vitamin B12 |
953 |
NORMAL
|
200-1100 pg/mL |
01 |
| FOLATE, SERUM |
|
| Folate, Serum |
16.5 |
NORMAL
|
ng/mL |
01 |
|
Reference Range
Low: <3.4
Borderline: 3.4-5.4
Normal: >5.4
|
| FIBRINOGEN ACTIVITY, CLAUSS |
|
| Fibrinogen Activity, Clauss |
227 |
NORMAL
|
175-425 mg/dL |
01 |
| CORTISOL, TOTAL |
|
| Cortisol, Total |
13.4 |
NORMAL
|
mcg/dL |
01 |
|
Reference Range: For 8 a.m.(7-9 a.m.) Specimen: 4.0-22.0
Reference Range: For 4 p.m.(3-5 p.m.) Specimen: 3.0-17.0
* Please interpret above results accordingly *
|
| DHEA SULFATE |
|
| DHEA Sulfate |
315 |
NORMAL
|
93-415 mcg/dL |
01 |
| RHEUMATOID FACTOR |
|
| Rheumatoid Factor |
<10 |
NORMAL
|
<14 IU/mL |
01 |
| URINALYSIS, COMPLETE |
|
| Bacteria |
NONE SEEN |
NORMAL
|
|
01 |
|
This urine was analyzed for the presence of WBC,
RBC, bacteria, casts, and other formed elements.
Only those elements seen were reported.
|
| Squamous Epithelial Cells |
NONE SEEN |
NORMAL
|
|
01 |
|
This urine was analyzed for the presence of WBC,
RBC, bacteria, casts, and other formed elements.
Only those elements seen were reported.
|
| RBC |
NONE SEEN |
NORMAL
|
|
01 |
|
This urine was analyzed for the presence of WBC,
RBC, bacteria, casts, and other formed elements.
Only those elements seen were reported.
|
| WBC |
NONE SEEN |
NORMAL
|
|
01 |
|
This urine was analyzed for the presence of WBC,
RBC, bacteria, casts, and other formed elements.
Only those elements seen were reported.
|
| Leukocyte Esterase |
NEGATIVE |
NORMAL
|
|
01 |
|
This urine was analyzed for the presence of WBC,
RBC, bacteria, casts, and other formed elements.
Only those elements seen were reported.
|
| Nitrite |
NEGATIVE |
NORMAL
|
|
01 |
|
This urine was analyzed for the presence of WBC,
RBC, bacteria, casts, and other formed elements.
Only those elements seen were reported.
|
| Occult Blood |
NEGATIVE |
NORMAL
|
|
01 |
|
This urine was analyzed for the presence of WBC,
RBC, bacteria, casts, and other formed elements.
Only those elements seen were reported.
|
| Ketones |
NEGATIVE |
NORMAL
|
|
01 |
|
This urine was analyzed for the presence of WBC,
RBC, bacteria, casts, and other formed elements.
Only those elements seen were reported.
|
| Bilirubin |
NEGATIVE |
NORMAL
|
|
01 |
|
This urine was analyzed for the presence of WBC,
RBC, bacteria, casts, and other formed elements.
Only those elements seen were reported.
|
| Glucose |
NEGATIVE |
NORMAL
|
|
01 |
|
This urine was analyzed for the presence of WBC,
RBC, bacteria, casts, and other formed elements.
Only those elements seen were reported.
|
| PH |
5.5 |
NORMAL
|
|
01 |
|
This urine was analyzed for the presence of WBC,
RBC, bacteria, casts, and other formed elements.
Only those elements seen were reported.
|
| Specific Gravity |
1.011 |
NORMAL
|
|
01 |
|
This urine was analyzed for the presence of WBC,
RBC, bacteria, casts, and other formed elements.
Only those elements seen were reported.
|
| Appearance |
CLEAR |
NORMAL
|
|
01 |
|
This urine was analyzed for the presence of WBC,
RBC, bacteria, casts, and other formed elements.
Only those elements seen were reported.
|
| Color |
YELLOW |
NORMAL
|
|
01 |
|
This urine was analyzed for the presence of WBC,
RBC, bacteria, casts, and other formed elements.
Only those elements seen were reported.
|
| Protein |
NEGATIVE |
NORMAL
|
|
01 |
|
This urine was analyzed for the presence of WBC,
RBC, bacteria, casts, and other formed elements.
Only those elements seen were reported.
|
| Hyaline CAST |
NONE SEEN |
NORMAL
|
|
01 |
|
This urine was analyzed for the presence of WBC,
RBC, bacteria, casts, and other formed elements.
Only those elements seen were reported.
|
| INSULIN |
|
| Insulin |
2.3 |
NORMAL
|
uIU/mL |
01 |
|
Reference Range < or = 18.4
Risk:
Optimal < or = 18.4
Moderate NA
High >18.4
Adult cardiovascular event risk category
cut points (optimal, moderate, high)
are based on Insulin Reference Interval
studies performed at Quest Diagnostics
in 2022.
|
| C-REACTIVE PROTEIN |
|
| C-Reactive Protein |
<3.0 |
NORMAL
|
<8.0 mg/L |
01 |
| PSA, TOTAL |
|
| PSA, Total |
0.28 |
NORMAL
|
< OR = 4.00 ng/mL |
01 |
|
The total PSA value from this assay system is
standardized against the WHO standard. The test
result will be approximately 20% lower when compared
to the equimolar-standardized total PSA (Beckman
Coulter). Comparison of serial PSA results should be
interpreted with this fact in mind.
This test was performed using the Siemens
chemiluminescent method. Values obtained from
different assay methods cannot be used
interchangeably. PSA levels, regardless of
value, should not be interpreted as absolute
evidence of the presence or absence of disease.
|
| CA 125 |
|
| CA 125 |
5 |
NORMAL
|
<35 U/mL |
01 |
|
This test was performed using the Siemens
Chemiluminescent method. Values obtained from
different assay methods cannot be used
interchangeably. CA 125 levels, regardless of
value, should not be interpreted as absolute
evidence of the presence or absence of disease.
|
| THYROGLOBULIN ANTIBODIES |
|
| Thyroglobulin Antibodies |
<1 |
NORMAL
|
< or = 2 IU/mL |
01 |
|
The cutoff value of < or = 2 IU/mL represents the lower
limit of quantification (LOQ) established by the assay
manufacturer (Beckman Coulter). While very low levels
of TgAb may not be clinically significant, any
measurable TgAb above LOQ has the potential for
interference with Thyroglobulin assay. The
manufacturer of the assay found that 96% of the
participants in a healthy population (no evidence of
thyroid or autoimmune disease) had TgAb levels below
4 IU/mL.
|
| PROLACTIN |
|
| Prolactin |
6.6 |
NORMAL
|
2.0-18.0 ng/mL |
01 |
| T3, FREE |
|
| T3, Free |
4.0 |
NORMAL
|
2.3-4.2 pg/mL |
01 |
| FSH |
|
| FSH |
<0.7 |
LOW
|
1.4-12.8 mIU/mL |
01 |
| LH |
|
| LH |
6.6 |
NORMAL
|
1.5-9.3 mIU/mL |
01 |
| HEMOGLOBIN A1c |
|
| Hemoglobin A1C |
5.0 |
NORMAL
|
<5.7 % |
01 |
|
For the purpose of screening for the presence of
diabetes:
<5.7% Consistent with the absence of diabetes
5.7-6.4% Consistent with increased risk for diabetes
(prediabetes)
> or =6.5% Consistent with diabetes
This assay result is consistent with a decreased risk
of diabetes.
Currently, no consensus exists regarding use of
hemoglobin A1c for diagnosis of diabetes in children.
According to American Diabetes Association (ADA)
guidelines, hemoglobin A1c <7.0% represents optimal
control in non-pregnant diabetic patients. Different
metrics may apply to specific patient populations.
Standards of Medical Care in Diabetes(ADA).
|
| GGT |
|
| GGT |
18 |
NORMAL
|
3-90 U/L |
01 |
| MAGNESIUM |
|
| Magnesium |
2.2 |
NORMAL
|
1.5-2.5 mg/dL |
01 |
| CREATINE KINASE, TOTAL |
|
| Creatine Kinase, Total |
792 |
HIGH
|
26-366 U/L |
01 |
|
Results verified by repeat analysis on dilution.
|
| COMPREHENSIVE METABOLIC PANEL |
|
| Urea Nitrogen (BUN) |
26 |
HIGH
|
9-46 U/L |
01 |
| Creatinine |
1.34 |
HIGH
|
9-46 U/L |
01 |
| AST |
21 |
NORMAL
|
9-46 U/L |
01 |
| Glucose |
87 |
NORMAL
|
9-46 U/L |
01 |
| EGFR |
71 |
NORMAL
|
9-46 U/L |
01 |
| BUN/Creatinine Ratio |
19 |
NORMAL
|
9-46 U/L |
01 |
| Sodium |
139 |
NORMAL
|
9-46 U/L |
01 |
| Potassium |
4.2 |
NORMAL
|
9-46 U/L |
01 |
| Chloride |
105 |
NORMAL
|
9-46 U/L |
01 |
| Carbon Dioxide |
25 |
NORMAL
|
9-46 U/L |
01 |
| Calcium |
9.9 |
NORMAL
|
9-46 U/L |
01 |
| Protein, Total |
7.4 |
NORMAL
|
9-46 U/L |
01 |
| Albumin |
5.0 |
NORMAL
|
9-46 U/L |
01 |
| Globulin |
2.4 |
NORMAL
|
9-46 U/L |
01 |
| Albumin/Globulin Ratio |
2.1 |
NORMAL
|
9-46 U/L |
01 |
| Bilirubin, Total |
0.6 |
NORMAL
|
9-46 U/L |
01 |
| Alkaline Phosphatase |
59 |
NORMAL
|
9-46 U/L |
01 |
| ALT |
29 |
NORMAL
|
9-46 U/L |
01 |
| LD |
|
| LD |
134 |
NORMAL
|
100-220 U/L |
01 |
| TSH |
|
| TSH |
2.88 |
NORMAL
|
0.40-4.50 mIU/L |
01 |
| T4, FREE |
|
| T4, Free |
1.2 |
NORMAL
|
0.8-1.8 ng/dL |
01 |
| IRON, TOTAL |
|
| Iron, Total |
157 |
NORMAL
|
50-180 mcg/dL |
01 |
| URIC ACID |
|
| Uric Acid |
3.8 |
LOW
|
4.0-8.0 mg/dL |
01 |
|
Therapeutic target for gout patients: <6.0 mg/dL
|
| PHOSPHATE (AS PHOSPHORUS) |
|
| Phosphate (AS Phosphorus) |
2.6 |
NORMAL
|
2.5-4.5 mg/dL |
01 |
| CBC (INCLUDES DIFF/PLT) |
|
| White Blood Cell Count |
6.1 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| Red Blood Cell Count |
4.41 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| Hemoglobin |
13.0 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| Hematocrit |
39.0 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| MCV |
88.4 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| MCH |
29.5 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| MCHC |
33.3 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| RDW |
12.0 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| Platelet Count |
295 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| MPV |
9.4 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| Absolute Neutrophils |
3520 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| Absolute Lymphocytes |
2098 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| Absolute Monocytes |
348 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| Absolute Eosinophils |
92 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| Absolute Basophils |
43 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| Neutrophils |
57.7 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| Lymphocytes |
34.4 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| Monocytes |
5.7 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| Eosinophils |
1.5 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| Basophils |
0.7 |
NORMAL
|
% |
01 |
|
This sample was analyzed for abnormalities in WBCs, RBCs
and Platelets. Only significant findings have been
reported.
|
| FERRITIN |
|
| Ferritin |
363 |
NORMAL
|
38-380 ng/mL |
01 |
| PROTHROMBIN TIME-INR |
|
| PT |
11.5 |
NORMAL
|
9.0-11.5 sec |
01 |
|
For additional information, please refer to
http://education.questdiagnostics.com/faq/FAQ104
(This link is being provided for informational/
educational purposes only.)
|
| INR |
1.1 |
NORMAL
|
9.0-11.5 sec |
01 |
|
For additional information, please refer to
http://education.questdiagnostics.com/faq/FAQ104
(This link is being provided for informational/
educational purposes only.)
|
| HEPATIC FUNCTION PANEL |
|
| Globulin |
2.3 |
NORMAL
|
9-46 U/L |
01 |
| Protein, Total |
7.1 |
NORMAL
|
9-46 U/L |
01 |
| Albumin |
4.8 |
NORMAL
|
9-46 U/L |
01 |
| Albumin/Globulin Ratio |
2.1 |
NORMAL
|
9-46 U/L |
01 |
| Bilirubin, Total |
0.6 |
NORMAL
|
9-46 U/L |
01 |
| Bilirubin, Direct |
0.1 |
NORMAL
|
9-46 U/L |
01 |
| Bilirubin, Indirect |
0.5 |
NORMAL
|
9-46 U/L |
01 |
| Alkaline Phosphatase |
46 |
NORMAL
|
9-46 U/L |
01 |
| AST |
19 |
NORMAL
|
9-46 U/L |
01 |
| ALT |
40 |
NORMAL
|
9-46 U/L |
01 |
| AMYLASE |
|
| Amylase |
135 |
HIGH
|
21-101 U/L |
01 |
| SED RATE BY MODIFIED WESTERGREN |
|
| SED Rate By Modified Westergren |
9 |
NORMAL
|
< OR = 15 mm/h |
01 |
| T4 (THYROXINE), TOTAL |
|
| T4 (Thyroxine), Total |
6.5 |
NORMAL
|
4.9-10.5 mcg/dL |
01 |
| ESTRADIOL |
|
| Estradiol |
90 |
HIGH
|
pg/mL |
01 |
|
Reference Range
Female:
Follicular Phase: 30-144
Mid-Cycle: 64-357
Luteal Phase: 56-214
Postmenopausal: < or = 31
Reference range established on post-pubertal patient
population. No pre-pubertal reference range
established using this assay. For any patients for
whom low Estradiol levels are anticipated (e.g. males,
pre-pubertal children and hypogonadal/post-menopausal
females), the Quest Diagnostics Nichols Institute
Estradiol, Ultrasensitive, LCMSMS assay is recommended
(order code 30289).
Please note: patients being treated with the drug
fulvestrant (Faslodex(R)) have demonstrated significant
interference in immunoassay methods for estradiol
measurement. The cross reactivity could lead to falsely
elevated estradiol test results leading to an
inappropriate clinical assessment of estrogen status.
Quest Diagnostics order code 30289-Estradiol,
Ultrasensitive LC/MS/MS demonstrates negligible cross
reactivity with fulvestrant.
|
| TESTOSTERONE, FREE (DIALYSIS) AND TOTAL (MS) |
|
| Testosterone, Total, MS |
641 |
NORMAL
|
35.0-155.0 pg/mL |
01 |
|
This test was developed and its analytical performance
characteristics have been determined by Quest Diagnostics.
It has not been cleared or approved by the FDA. This assay
has been validated pursuant to the CLIA regulations and is
used for clinical purposes.
|
| Testosterone, Free |
84.6 |
NORMAL
|
35.0-155.0 pg/mL |
01 |
|
This test was developed and its analytical performance
characteristics have been determined by Quest Diagnostics.
It has not been cleared or approved by the FDA. This assay
has been validated pursuant to the CLIA regulations and is
used for clinical purposes.
|
| SEX HORMONE BINDING GLOBULIN |
|
| Sex Hormone Binding Globulin |
48 |
NORMAL
|
10-50 nmol/L |
01 |
| QUESTASSURED(TM) 25 HYDROXYVITAMIN D(D2,D3) |
|
| Vitamin D, 25-OH, Total |
50 |
NORMAL
|
ng/mL |
01 |
|
(Note)
Reference range: Not established
This test was developed and its analytical performance
characteristics have been determined by medfusion. It has
not been cleared or approved by the US Food and Drug
Administration. This assay has been validated pursuant to
the CLIA regulation and is used for Clinical purposes.
MDF
med fusion
2501 South State Highway 121,Suite 1100
Lewisville TX 75067
972-966-7300
Ithiel James L. Frame, MD, PhD
See Note 1
Note 1
For additional information, please refer to
http://education.QuestDiagnostics.com/faq/FAQ199
(This link is being provided for informational/
educational purposes only.)
|
| Vitamin D, 25-OH, D3 |
50 |
NORMAL
|
ng/mL |
01 |
|
(Note)
Reference range: Not established
This test was developed and its analytical performance
characteristics have been determined by medfusion. It has
not been cleared or approved by the US Food and Drug
Administration. This assay has been validated pursuant to
the CLIA regulation and is used for Clinical purposes.
MDF
med fusion
2501 South State Highway 121,Suite 1100
Lewisville TX 75067
972-966-7300
Ithiel James L. Frame, MD, PhD
See Note 1
Note 1
For additional information, please refer to
http://education.QuestDiagnostics.com/faq/FAQ199
(This link is being provided for informational/
educational purposes only.)
|
| Vitamin D, 25-OH, D2 |
<4 |
NORMAL
|
ng/mL |
01 |
|
(Note)
Reference range: Not established
This test was developed and its analytical performance
characteristics have been determined by medfusion. It has
not been cleared or approved by the US Food and Drug
Administration. This assay has been validated pursuant to
the CLIA regulation and is used for Clinical purposes.
MDF
med fusion
2501 South State Highway 121,Suite 1100
Lewisville TX 75067
972-966-7300
Ithiel James L. Frame, MD, PhD
See Note 1
Note 1
For additional information, please refer to
http://education.QuestDiagnostics.com/faq/FAQ199
(This link is being provided for informational/
educational purposes only.)
|
| APOLIPOPROTEIN EVALUATION |
|
| Apolipoprotein B |
96 |
HIGH
|
|
01 |
|
Reference Range <0.77
Risk Category:
Optimal <0.77
Moderate 0.77-0.95
High >0.95
Cardiovascular event risk category
cut points (optimal, moderate, high)
are based on the AMORIS study,
(Walldius G, Jungner I.
2004 doi:10.1046/j.1365-2796.2003.
01276.x)
|
| Apolipoprotein A1 |
155 |
NORMAL
|
|
01 |
|
Reference Range <0.77
Risk Category:
Optimal <0.77
Moderate 0.77-0.95
High >0.95
Cardiovascular event risk category
cut points (optimal, moderate, high)
are based on the AMORIS study,
(Walldius G, Jungner I.
2004 doi:10.1046/j.1365-2796.2003.
01276.x)
|
| Apolipoprotein B/A1 Ratio |
0.62 |
NORMAL
|
|
01 |
|
Reference Range <0.77
Risk Category:
Optimal <0.77
Moderate 0.77-0.95
High >0.95
Cardiovascular event risk category
cut points (optimal, moderate, high)
are based on the AMORIS study,
(Walldius G, Jungner I.
2004 doi:10.1046/j.1365-2796.2003.
01276.x)
|
| IGF 1, LC/MS |
|
| IGF 1, LC/MS |
199 |
NORMAL
|
-2.0 - +2.0 SD |
01 |
|
This test was developed and its analytical performance
characteristics have been determined by Quest Diagnostics.
It has not been cleared or approved by the FDA. This assay
has been validated pursuant to the CLIA regulations and is
used for clinical purposes.
|
| Z Score (Female) |
0.0 |
NORMAL
|
-2.0 - +2.0 SD |
01 |
|
This test was developed and its analytical performance
characteristics have been determined by Quest Diagnostics.
It has not been cleared or approved by the FDA. This assay
has been validated pursuant to the CLIA regulations and is
used for clinical purposes.
|
| LIPID PANEL, STANDARD |
|
| HDL Cholesterol |
54 |
NORMAL
|
<130 mg/dL (calc) |
01 |
|
For patients with diabetes plus 1 major ASCVD risk
factor, treating to a non-HDL-C goal of <100 mg/dL
(LDL-C of <70 mg/dL) is considered a therapeutic
option.
|
| Triglycerides |
53 |
NORMAL
|
<130 mg/dL (calc) |
01 |
|
For patients with diabetes plus 1 major ASCVD risk
factor, treating to a non-HDL-C goal of <100 mg/dL
(LDL-C of <70 mg/dL) is considered a therapeutic
option.
|
| CHOL/HDLC Ratio |
3.0 |
NORMAL
|
<130 mg/dL (calc) |
01 |
|
For patients with diabetes plus 1 major ASCVD risk
factor, treating to a non-HDL-C goal of <100 mg/dL
(LDL-C of <70 mg/dL) is considered a therapeutic
option.
|
| Non HDL Cholesterol |
106 |
NORMAL
|
<130 mg/dL (calc) |
01 |
|
For patients with diabetes plus 1 major ASCVD risk
factor, treating to a non-HDL-C goal of <100 mg/dL
(LDL-C of <70 mg/dL) is considered a therapeutic
option.
|
| Cholesterol, Total |
160 |
NORMAL
|
<130 mg/dL (calc) |
01 |
|
For patients with diabetes plus 1 major ASCVD risk
factor, treating to a non-HDL-C goal of <100 mg/dL
(LDL-C of <70 mg/dL) is considered a therapeutic
option.
|
| LDL-Cholesterol |
92 |
NORMAL
|
<130 mg/dL (calc) |
01 |
|
For patients with diabetes plus 1 major ASCVD risk
factor, treating to a non-HDL-C goal of <100 mg/dL
(LDL-C of <70 mg/dL) is considered a therapeutic
option.
|
| PTH, INTACT WITHOUT CALCIUM |
|
| Parathyroid Hormone, Intact |
93 |
HIGH
|
16-77 pg/mL |
01 |
|
Interpretive Guide Intact PTH Calcium
------------------ ---------- -------
Normal Parathyroid Normal Normal
Hypoparathyroidism Low or Low Normal Low
Hyperparathyroidism
Primary Normal or High High
Secondary High Normal or Low
Tertiary High High
Non-Parathyroid
Hypercalcemia Low or Low Normal High
|